Is Aranesp used in dialysis patients?
Yes. Aranesp (darbepoetin alfa) is used to treat anemia in people with chronic kidney disease, including patients on dialysis, because their kidneys do not make enough erythropoietin. Aranesp works by stimulating red blood cell production to help raise hemoglobin levels and reduce the need for red blood cell transfusions.
How is Aranesp different for dialysis vs non-dialysis kidney disease?
The dosing schedule and how closely hemoglobin is monitored can differ depending on whether someone is on dialysis and how their anemia responds. The main clinical goal is the same: improve anemia from reduced kidney erythropoietin production while avoiding hemoglobin levels that rise too high, which can increase risk.
What do dialysis patients typically use Aranesp for?
Dialysis patients typically receive Aranesp to treat anemia related to chronic kidney disease. Clinicians monitor hemoglobin and iron status, since low iron can limit how well any erythropoiesis-stimulating agent (ESA) works.
What safety issues do dialysis patients need to know?
The biggest safety issue with ESAs like Aranesp is that targeting too high a hemoglobin level can increase risk of serious cardiovascular events and stroke. That is why hemoglobin is monitored regularly and dosing is adjusted based on response.
Related question: Is Aranesp the only anemia option in dialysis?
No. Dialysis patients may also need iron replacement (oral or IV) and, in some cases, transfusions. Aranesp is one tool, used when ESA therapy is appropriate and when iron stores support red blood cell production.
Sources:
1. https://www.drugpatentwatch.com/